SCHEMBL4735877

SCHEMBL4735877

Cc1ccc(NC(=O)Nc2ccc(-c3ccc(C)c4noc(N)c34)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 18/20 0.58
KDR P35968 16/20 0.58
KIT P10721 11/20 0.58
PDGFRB P09619 5/20 0.58
FLT1 P17948 5/20 0.51
CSF1R P07333 4/20 0.51
LCK P06239 4/20 0.51
LYN P07948 4/20 0.51
FLT4 P35916 4/20 0.51
BLK P51451 4/20 0.51
FYN P06241 3/20 0.51
SRC P12931 3/20 0.51
DYRK3 O43781 3/20 0.51
ROCK2 O75116 3/20 0.51
MAP4K4 O95819 3/20 0.51
NTRK1 P04629 3/20 0.51
RET P07949 3/20 0.51
FER P16591 3/20 0.51
RPS6KB1 P23443 3/20 0.51
AXL P30530 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1379853 0.92 KDR (0.61) FLT3KDRKITPDGFRBFLT1
SCHEMBL1380780 0.92 FLT3 (0.58) FLT3KDRKITPDGFRBFLT1
SCHEMBL4739605 0.89 KDR (0.67) FLT3KDRKITPDGFRBFLT1
SCHEMBL1384165 0.89 FLT3 (0.59) FLT3KDRKITPDGFRBFLT1
SCHEMBL4787011 0.88 KDR (0.66) FLT3KDRKITPDGFRBFLT1
SCHEMBL1384184 0.88 KDR (0.59) FLT3KDRKITPDGFRBFLT1
SCHEMBL4740470 0.88 KDR (0.76) FLT3KDRKITPDGFRBFLT1
SCHEMBL4739508 0.85 KDR (0.63) FLT3KDRKITPDGFRBFLT1
SCHEMBL1381417 0.85 KDR (0.66) FLT3KDRKITPDGFRBFLT1
SCHEMBL4739506 0.85 KDR (0.58) FLT3KDRKITPDGFRBFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed